Eric Nuermberger, MD

Eric Nuermberger, M.D. is Associate Professor of Medicine and International Health at Johns Hopkins University. He has been involved in the development of new anti-tubercular agents since 2001. His research using in vitro and animal models of tuberculosis to optimize dosing of new and existing drugs and design optimal drug combinations has informed the clinical development of moxifloxacin, rifapentine, pretomanid, bedaquiline and sutezolid and the pre-clinical development of numerous other compounds. It is funded by the National Institutes of Health, the U.S. Food and Drug Administration, the Bill and Melinda Gates Foundation, the Global Alliance for TB Drug Development, and various pharmaceutical companies. Dr. Nuermberger is a member of the AIDS Clinical Trial Group’s TB Transformative Science Group and the Core Science Group of the TB Trials Consortium.  He is also Co-Chair of the Preclinical and Clinical Sciences Work Group of the Critical Path to TB Drug Regimens (CPTR) initiative. Dr. Nuermberger also serves as an Associate Editor of the Antimicrobial Agents and Chemotherapy and the International Journal of TB and Lung Disease.

  • Investigator, TB Transformative Science Group (Dec 2016-Nov 2018)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5308: A Prospective, Single-Arm, Open-Label Study to...

This study is being done with people who are infected with HIV, but do not show any signs of having HIV. They are also feeling...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More